NCT03373097View on ClinicalTrials.gov

Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 5, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

NeuroblastomaNeuroblastoma RecurrentGD2-positive Solid TumorsOsteosarcomaEwing SarcomaSarcoma

Interventions

BIOLOGICAL

GD2-CART01

Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.

Trial Locations (1)

Unknown

Ospedale Pediatrico Bambino Gesù, Roma

All Listed Sponsors

lead

Bambino Gesù Hospital and Research Institute

OTHER

NCT03373097 - Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | Biotech Hunter | Biotech Hunter